The Paraclete as Christian Muse: Audience-Critical Reflections on the Fourth Gospel’s Extrahistorical Claims
Journal of Biblical Literature · 15.06.2026 · 145 (2) · 281-303
DOI: 10.15699/jbl.1452.2026.5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biblical Literature, online erschienen am 15.06.2026. Verfasst von Sanghwan Lee.
Abstract (Originalsprache)
The Fourth Gospel employs familiar authentication strategies such as historical referentiality, eyewitness testimony, and scriptural citation. Yet it also contains extrahistorical claims—most notably Jesus’s preexistence and incarnation—that these conventional devices cannot substantiate. Through an audience-critical lens, I explore how such claims might have been rendered credible to a myth-informed Greco-Roman audience. From this perspective, ancient hearers may have understood the Johannine Paraclete through conceptual categories shaped by the Greco-Roman tradition of the Muses, the inspirational and omniscient goddesses of literature. As the one who teaches, guides, and discloses hidden truth, the Paraclete could have functioned for such audiences as a Christian analogue to the Muses, providing a culturally intelligible framework through which the gospel’s extrahistorical dimensions could be received as credible.
Zitieren
APA
Lee, S. (2026). The Paraclete as Christian Muse: Audience-Critical Reflections on the Fourth Gospel’s Extrahistorical Claims. Journal of Biblical Literature, 145(2), 281-303. https://doi.org/10.15699/jbl.1452.2026.5
Vancouver
Lee S. The Paraclete as Christian Muse: Audience-Critical Reflections on the Fourth Gospel’s Extrahistorical Claims. Journal of Biblical Literature. 2026;145(2):281-303. doi:10.15699/jbl.1452.2026.5
BibTeX
@article{Lee2026,
author = {Lee, Sanghwan},
title = {The Paraclete as Christian Muse: Audience-Critical Reflections on the Fourth Gospel’s Extrahistorical Claims},
journal = {Journal of Biblical Literature},
year = {2026},
volume = {145},
number = {2},
pages = {281--303},
doi = {10.15699/jbl.1452.2026.5}
}
EUVIMED